{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "MMED",
  "name": "MiniMed Group, Inc.",
  "url": "https://orbyd.app/dossiers/MMED/",
  "json_url": "https://orbyd.app/dossiers/MMED.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Carve-out re-rate re-firing: MMED closed $16.93 on 2026-07-17 (+6.61%, volume 26% above average, intraday $17.15), reclaiming the $17 handle for the first time since the June fade — on group confirmation from Abbott's 07-16 print and DXCM's ~7.2% run. Still 17.4% below its $20 IPO with sell-side at $20.60–$21.33. The ~08-10 Q1 print and Medtronic's undated 90.03% distribution are the two swing factors.",
  "invalidation_trigger": "A daily close below $15.40 surrenders the 2026-07-17 breakout base and returns price to the July chop; secondary: the ~2026-08-10 Q1 print showing organic growth below the 8.7% Q4 pace or a cut to the FY2027 ~10% organic / ~16% EBITDA margin guide, or Medtronic announcing a pro-rata spin that floods the ~10% float.",
  "catalyst_date": "2026-08-10",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "MMED in this dossier = MiniMed Group, Inc. (Medtronic diabetes spinoff) — NOT MindMed/psychedelics; web sources on ticker MMED may resolve to the wrong company.",
    "Q4 FY2026 already printed 2026-06-03 (rev $837M beat, EPS $(0.68) big miss); next earnings ~early Sept 2026 — no earnings blackout inside the next 30 days.",
    "Abbott is a frenemy: Libre CGM competes with MiniMed sensors, yet partners on the exclusive dual glucose-ketone sensor.",
    "Wells Fargo Overweight but cut PT to $22 on 2026-06-04 — track price vs that target as the headroom gauge.",
    "ADA Scientific Sessions date (~2026-06-20) is an estimate based on prior-year mid-June timing; confirm exact dates before treating as a hard catalyst.",
    "MMED = MiniMed Group, Inc., Medtronic's diabetes carve-out (Nasdaq IPO 2026-03-06, 28M sh @ $20, ~$560M raised) — NOT MindMed/psychedelics. Current data sources resolve the ticker correctly to MiniMed.",
    "Next earnings CONFIRMED for 2026-08-10 (Q1 FY2027); no earnings blackout inside the next 30 days.",
    "June 3 2026 catalysts (Q4 print + Abbott dual-sensor deal) have already fired and fully round-tripped — they sit in the base, not upcoming.",
    "Abbott dual glucose-ketone sensor is pending FDA approval, not yet commercial; Abbott is a frenemy (Libre CGM competes with MiniMed's own sensors).",
    "Prior theme_discovery label 'biotech-precision-therapeutics' is a mis-map for a diabetes-device maker; corrected to device/AID/spinoff themes.",
    "Key levels: $10.65 52-week low = structural floor; $17-18 reclaim = first base signal; ~$20.91 consensus target = headroom gauge; $20 IPO the June spike failed to hold.",
    "Q4 FY26 (2026-06-03): rev $837M vs $826.52M consensus (+1.3%), 8.7% organic, adj standalone EBITDA $154M (+32% YoY, 18.4% margin). FY26 crossed $3B rev; net loss widened to ~$333M.",
    "MMED in this dossier = MiniMed Group, Inc. (Medtronic diabetes carve-out, Nasdaq IPO 2026-03-06, 28M sh @ $20, $560M gross / $538M net) — NOT MindMed/psychedelics and NOT Medifast. Stockscan.io resolves MMED to Medifast; verify company identity on any third-party MMED data before trusting it.",
    "Next earnings ~2026-08-10 (Q1 FY2027) per stockanalysis.com; Yahoo Finance lists 2026-08-17 as an estimate. Confirm the exact date before treating it as a hard blackout.",
    "Float is ~10%. Medtronic has stated intent to distribute via spin-off, split-off or combination but explicitly has NO obligation to complete it, and no date is public. Split-off (exchange offer) absorbs better than a pro-rata spin — the structure of the announcement matters more than the fact of it.",
    "The 2026-07-17 +6.61% move had NO company-specific catalyst — MiniMed's newsroom shows zero July 2026 press releases. Driver was sector: Abbott's 2026-07-16 print lifted medtech, DXCM ran ~7.2% into Health Canada G7 15-day authorization (2026-07-13), and Deutsche Bank initiated DXCM Buy $86 / PODD Buy $190 / TNDM Hold $15.50 in late June. Borrowed momentum — track whether it holds independently.",
    "MiniMed Flex: FDA cleared 2026-03-18, U.S. commercial launch 2026-06-17. Smallest pump, first smartphone-controlled design, 300u reservoir, SmartGuard with Meal Detection. T1D 7+, T2D 18+. Launched with Simplera Sync sensor; Flex + Abbott Instinct pairing guided 'later this summer' — no firm date.",
    "Abbott is a frenemy: supplies Instinct sensor (780G integration FDA-cleared, plus T2D indication) and the pending dual glucose-ketone sensor (CE Mark held, FDA under review, no launch timeline), while Libre CGM competes directly with MiniMed's own sensors.",
    "Key levels: $15.40 = 2026-07-16 low, floor of the 07-17 breakout base; $13.66 = reported 50-day SMA; $10.65 = 52-week low / structural floor; $17-18 = first resistance shelf; $20 = IPO price the June spike failed to hold; $20.48 = 52-week high; $20.60-$21.33 = consensus target band (Goldman $24 raised 2026-06-04, BTIG $25, Evercore $20, MS OW $19, Benchmark Buy $20 reiterated mid-July on 10-K model update).",
    "Q4 FY26 (2026-06-03): rev $837M vs $826.52M consensus (+1.3% beat), +15.6% reported / 8.7% organic; EPS -$0.68 vs -$0.22 est (large miss); net loss attributable $183M for the quarter, ~$333M FY26. TTM rev $3.10B +14.3%, TTM EPS -$1.30. Market cap $4.75B.",
    "FY2027 guide: ~10% organic revenue growth INCLUDING 1.0-1.5pts from an extra week (implies ~8.5-9% true organic — continued deceleration), ~16% adjusted EBITDA margin. No EPS guidance given.",
    "Board additions 2026-06-29: David Endicott (Alcon CEO) and Linnea Burman.",
    "Prior theme label 'biotech-precision-therapeutics' from theme_discovery is a mis-map for a diabetes-device maker; corrected to device/AID/spinoff themes.",
    "GLP-1 complex (LLY/NVO) is the standing structural bear correlation for the whole insulin-delivery hardware group — watch for any datapoint on GLP-1 adoption compressing pump patient starts."
  ],
  "body_markdown": "## Current Thesis\n\nMiniMed is Medtronic's diabetes business carved out into a standalone public company (Nasdaq IPO 2026-03-06, 28M shares at $20, ~$560M gross / $538M net). The narrative being bought is the only vendor selling a fully integrated diabetes stack — insulin pumps, smart pens, CGMs, sensors and the dosing algorithm — repricing as a focused growth franchise once the parent's overhang clears.\n\nFor most of Q2 that story was dead tape. The 2026-06-03 print-plus-Abbott spike round-tripped in full, and the stock spent early July grinding $15.29–$15.88. The last two sessions changed the structure: MMED closed 2026-07-17 at $16.93, +6.61% on 1.23M shares (26% above the 973,886 average), with an intraday print of $17.15 — a +9.9% two-day move off the 2026-07-16 low of $15.40. That is the first reclaim of the $17 handle since the June fade, and it did not happen alone. Abbott's 2026-07-16 quarterly lifted medtech broadly, Dexcom ran ~7.2% into Health Canada's 2026-07-13 authorization of the G7 15-day system, and Deutsche Bank initiated DXCM (Buy, $86) and PODD (Buy, $190) in late June. The diabetes-device group is moving together, which is what separates a bounce from a base.\n\nThe honest caveat: the trigger was borrowed. Nothing company-specific printed on 2026-07-16 or 07-17 — MiniMed's newsroom shows no July release. This is a carve-out re-rating on group beta with a first product-cycle leg underneath it, priced 17.4% below its own IPO.\n\n## Bull Case\n\n- **Full-stack integration, and the products are shipping.** MiniMed Flex — the company's smallest pump, first smartphone-controlled design, 300-unit reservoir — cleared FDA 2026-03-18 and went commercially available in the U.S. on 2026-06-17, launching with the Simplera Sync sensor. Approved for T1D age 7+ and insulin-dependent T2D 18+.\n- **Instinct integration is the next dated leg.** The Flex-plus-Instinct (Abbott sensor) launch is guided for \"later this summer,\" and the 780G already holds FDA clearance for Instinct plus a T2D indication. Instinct sensors launched in Europe 2026-06-23.\n- **Revenue base is real.** $3.10B trailing revenue, +14.3% YoY; Q4 FY2026 revenue of $837M (2026-06-03) grew 15.6% reported and beat the $826.52M consensus.\n- **Guidance is not a reset.** FY2027 outlook calls for ~10% organic growth (including 1.0–1.5pts from an extra week) at a ~16% adjusted EBITDA margin.\n- **Sell side sits above spot.** Consensus target $20.60–$21.33 across 11–15 analysts; Goldman raised to $24 on 2026-06-04 on margin outperformance, BTIG $25, Evercore $20, Morgan Stanley Overweight $19, William Blair Outperform. Benchmark reiterated Buy/$20 in mid-July on a post-10-K model update.\n- **Sector bid is confirmed, not solitary.** DXCM $72.59 and PODD $154.80 both carry fresh Buy initiations; the CGM/AID category is being marked up as a group.\n\n## Bear Case\n\n- Medtronic has stated it intends a tax-free distribution — spin-off, split-off, or a combination — and has explicitly stated *no obligation* to complete it. Until that mechanism is announced, the float is ~10% and every re-rate runs into a pending supply event with no date attached.\n- **Organic growth decelerated.** The IPO deck leaned on consecutive double-digit organic quarters; Q4 FY2026 printed 8.7% organic. Stripping the extra-week benefit, the FY2027 ~10% guide implies roughly 8.5–9% true organic — a continuation of the slowdown, not a reacceleration.\n- **The earnings line is ugly.** Q4 EPS of -$0.68 missed the -$0.22 estimate by a wide margin; net loss attributable was $183M for the quarter and roughly $333M for FY2026 (trailing EPS -$1.30). Separation costs are still embedded and standalone GAAP profitability is not in the model.\n- **Still a busted IPO on the chart.** $16.93 against a $20 IPO and a $20.48 52-week high; the 52-week low is $10.65.\n- **Abbott is a frenemy.** Libre competes directly with MiniMed's own sensors while Abbott supplies Instinct and the dual glucose-ketone sensor. The ketone sensor carries CE Mark but remains under FDA review with no disclosed launch timeline — an unbooked catalyst, not a shipping product.\n- **The move was sympathy.** A +6.6% day sourced from a competitor's earnings can be given back as fast when the group bid rotates out.\n\n## Setup & Price Structure\n\nPrice spent 2026-07-02 through 2026-07-16 in a tight $15.29–$15.88 range after the June fade exhausted itself, then broke out on 2026-07-17 to close $16.93 with volume 26% above average and an intraday $17.15. The $15.40 low of 2026-07-16 is now the base floor of that breakout; losing it on a close negates the two-day thrust and puts price back inside the July range.\n\nReported 50-day simple moving average of $13.66 leaves price roughly 24% extended above it — a function of the depressed May–June base rather than a parabolic run, so the extension reads as trend recovery rather than blowoff. Overhead structure is well defined: the $17–$18 shelf is the first real resistance band, the $20 IPO price is where the June spike failed, and $20.48 marks the 52-week high. Consensus around $20.60–$21.33 sits just above that, meaning the sell-side headroom and the technical ceiling coincide — the cluster of targets is a gauge, not an accelerant.\n\nGroup structure is the strongest input right now. The setup only holds as long as DXCM and PODD hold their own breakouts; a diabetes-device name with a 10% float does not sustain a re-rate against a rolling sector.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-10 — Q1 FY2027 earnings** (widely listed date; one data provider estimates 2026-08-17, so confirm before treating as fixed). The number that matters is organic growth against the 8.7% Q4 pace and the FY2027 ~10% guide. First quarter with Flex revenue contribution.\n- **\"Later this summer\" (est. 2026-08 to 2026-09) — MiniMed Flex + Abbott Instinct sensor U.S. launch.** No firm date disclosed; the pairing is the commercial proof of the Abbott relationship.\n- **Undated, live risk — Medtronic distribution mechanism announcement.** A spin-off or split-off/exchange-offer filing could land in any window. Direction of the price reaction depends entirely on structure: a split-off exchange offer retires Medtronic shares and is typically absorbed better than a pro-rata pro forma dump into index-insensitive holders.\n- **Undated — FDA decision on the Abbott dual glucose-ketone sensor.** Under review, CE Mark already held, no PDUFA-style public date.\n\n## What Would Change Our Mind\n\nA daily close below $15.40 surrenders the 2026-07-17 breakout base and returns the name to the July chop, at which point the reclaim thesis is simply wrong and the busted-IPO downtrend reasserts. Below that, a weekly close under $13.66 would break the reported 50-day and re-open the $10.65 structural floor.\n\nOn fundamentals: the 2026-08-10 print showing organic growth below the 8.7% Q4 pace, or any trim to the FY2027 ~10% organic / ~16% adjusted EBITDA margin framework, removes the reason the sell side carries $20+ targets. A Medtronic distribution structured as a pro-rata spin — dropping ~253M shares onto holders who did not choose a diabetes pure-play — is the supply event that caps this regardless of operating results.\n\nConstructively: a hold of the $17–$18 shelf into the print, with DXCM and PODD holding their own breakouts, would confirm the group leg is durable and shift the frame from mean-reversion bounce to a genuine carve-out re-rate.\n\n## Correlation Notes\n\n- **Diabetes-device cluster (DXCM, PODD, TNDM):** the primary correlation. Deutsche Bank's late-June initiations (DXCM Buy $86, PODD Buy $190, TNDM Hold $15.50) marked the group bid; MMED's July move tracked it rather than led it. TNDM's Hold rating and pharmacy-channel reset make it the weakest link — if it breaks, category-wide pricing pressure is the read.\n- **Abbott (ABT):** dual exposure. Abbott's 2026-07-16 print was the proximate driver of the medtech bid, and Abbott supplies both the Instinct sensor and the pending dual glucose-ketone sensor while Libre competes with MiniMed's in-house sensors. Abbott commentary on Libre share is a direct MiniMed input.\n- **Medtronic (MDT):** the controlling holder at 90.03%. MDT stock moves and MDT capital-allocation commentary are a leading indicator for the distribution timing that governs MMED's float.\n- **GLP-1 complex (LLY, NVO):** the standing structural bear correlation for insulin-delivery hardware. Any datapoint suggesting GLP-1 adoption is compressing insulin-pump patient starts hits the whole AID group at once.\n- **Broad medtech / XLV:** with a ~10% float and $4.75B market cap, MMED trades with high beta to sector sentiment and low resistance to flow in either direction.\n\n*Ticker note: MMED here is MiniMed Group, Inc., Medtronic's diabetes carve-out. Some sources and historical data resolve the ticker to unrelated companies (MindMed/psychedelics, Medifast) — verify company identity before trusting third-party MMED data.*",
  "first_seen": "2026-06-09",
  "last_analyzed": "2026-07-28T07:00:47+00:00",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}